JP2019525753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525753A5 JP2019525753A5 JP2019501644A JP2019501644A JP2019525753A5 JP 2019525753 A5 JP2019525753 A5 JP 2019525753A5 JP 2019501644 A JP2019501644 A JP 2019501644A JP 2019501644 A JP2019501644 A JP 2019501644A JP 2019525753 A5 JP2019525753 A5 JP 2019525753A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- residue
- cysteine
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382339.6A EP3269734A1 (en) | 2016-07-15 | 2016-07-15 | Methods and compositions for the treatment of cancer |
| EP16382339.6 | 2016-07-15 | ||
| PCT/EP2017/067998 WO2018011433A1 (en) | 2016-07-15 | 2017-07-17 | Methods and compositions for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525753A JP2019525753A (ja) | 2019-09-12 |
| JP2019525753A5 true JP2019525753A5 (enExample) | 2020-07-09 |
| JP7090593B2 JP7090593B2 (ja) | 2022-06-24 |
Family
ID=56497695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501644A Active JP7090593B2 (ja) | 2016-07-15 | 2017-07-17 | 癌の治療のための方法および組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11427621B2 (enExample) |
| EP (2) | EP3269734A1 (enExample) |
| JP (1) | JP7090593B2 (enExample) |
| KR (1) | KR102232500B1 (enExample) |
| CN (1) | CN109563151B (enExample) |
| AU (1) | AU2017295071B2 (enExample) |
| BR (1) | BR112019000732A2 (enExample) |
| EA (1) | EA201990298A1 (enExample) |
| ES (1) | ES2985967T3 (enExample) |
| HR (1) | HRP20241153T1 (enExample) |
| HU (1) | HUE067973T2 (enExample) |
| IL (1) | IL264176B2 (enExample) |
| MA (1) | MA45675B1 (enExample) |
| MD (1) | MD3484913T2 (enExample) |
| MX (1) | MX2019000346A (enExample) |
| PL (1) | PL3484913T3 (enExample) |
| RS (1) | RS65983B1 (enExample) |
| SG (1) | SG11201900021PA (enExample) |
| SM (1) | SMT202400360T1 (enExample) |
| WO (1) | WO2018011433A1 (enExample) |
| ZA (1) | ZA201900960B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101729826B1 (ko) * | 2015-01-09 | 2017-05-11 | 주식회사 동희산업 | 플라스틱 연료탱크의 제조방법 |
| KR101862239B1 (ko) * | 2016-07-07 | 2018-05-30 | 주식회사 동희산업 | 플라스틱 연료탱크의 제조방법 |
| KR101859583B1 (ko) * | 2016-07-07 | 2018-06-27 | 주식회사 동희산업 | 플라스틱 연료탱크의 제조방법 |
| EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
| EP3841114A4 (en) * | 2018-08-20 | 2022-06-08 | Helix Nanotechnologies, Inc. | METHODS AND COMPOSITIONS FOR RNA EXPRESSION OF MYC INHIBITORS |
| WO2020187998A1 (en) * | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
| TWI829893B (zh) * | 2019-03-19 | 2024-01-21 | 瓦爾希伯倫私人腫瘤研究基金會 | 診斷肺癌的方法 |
| KR102922015B1 (ko) * | 2019-10-17 | 2026-02-04 | 주식회사 나이벡 | Fer 티로신 키나아제 결합능이 있는 신규한 펩타이드 및 이의 용도 |
| KR102398339B1 (ko) * | 2020-01-09 | 2022-05-13 | 이화여자대학교 산학협력단 | 일산화질소 전달용 융합 펩타이드 및 이의 용도 |
| CN115397843A (zh) * | 2020-04-15 | 2022-11-25 | 杭州卫本医药科技有限公司 | 用于筛选药物的靶标多肽和筛选方法 |
| EP4361633A1 (en) | 2022-10-25 | 2024-05-01 | Peptomyc, S.L. | Method for predicting response to a cancer treatment |
| EP4446742A1 (en) | 2023-04-14 | 2024-10-16 | Peptomyc, S.L. | Method for assessing or monitoring the response to a cancer treatment |
| EP4473974A1 (en) * | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| EP1251170A3 (en) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| JPH11510389A (ja) | 1995-07-31 | 1999-09-14 | アメリカ合衆国 | 細胞タンパク質の機能を不活性化するためのタンパク質−タンパク質相互作用表面の拡張 |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
| JP2002537828A (ja) | 1999-03-10 | 2002-11-12 | フォゲン リミティド | 細胞への物質のデリバリー |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9241920B2 (en) * | 2011-10-27 | 2016-01-26 | New York University | Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression |
| EP2801370A1 (en) * | 2013-05-07 | 2014-11-12 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | Methods and compositions for the treatment of cancer |
| EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
-
2016
- 2016-07-15 EP EP16382339.6A patent/EP3269734A1/en not_active Withdrawn
-
2017
- 2017-07-17 EP EP17746413.8A patent/EP3484913B1/en active Active
- 2017-07-17 MA MA45675A patent/MA45675B1/fr unknown
- 2017-07-17 AU AU2017295071A patent/AU2017295071B2/en active Active
- 2017-07-17 HR HRP20241153TT patent/HRP20241153T1/hr unknown
- 2017-07-17 ES ES17746413T patent/ES2985967T3/es active Active
- 2017-07-17 MX MX2019000346A patent/MX2019000346A/es unknown
- 2017-07-17 MD MDE20190609T patent/MD3484913T2/ro unknown
- 2017-07-17 JP JP2019501644A patent/JP7090593B2/ja active Active
- 2017-07-17 KR KR1020197004495A patent/KR102232500B1/ko active Active
- 2017-07-17 WO PCT/EP2017/067998 patent/WO2018011433A1/en not_active Ceased
- 2017-07-17 EA EA201990298A patent/EA201990298A1/ru unknown
- 2017-07-17 SG SG11201900021PA patent/SG11201900021PA/en unknown
- 2017-07-17 CN CN201780043683.0A patent/CN109563151B/zh active Active
- 2017-07-17 US US16/317,850 patent/US11427621B2/en active Active
- 2017-07-17 HU HUE17746413A patent/HUE067973T2/hu unknown
- 2017-07-17 SM SM20240360T patent/SMT202400360T1/it unknown
- 2017-07-17 PL PL17746413.8T patent/PL3484913T3/pl unknown
- 2017-07-17 BR BR112019000732-6A patent/BR112019000732A2/pt active Search and Examination
- 2017-07-17 RS RS20240929A patent/RS65983B1/sr unknown
-
2019
- 2019-01-09 IL IL264176A patent/IL264176B2/en unknown
- 2019-02-14 ZA ZA2019/00960A patent/ZA201900960B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509935A5 (enExample) | ||
| Rafferty et al. | Peptide therapeutics and the pharmaceutical industry: barriers encountered translating from the laboratory to patients | |
| JP2018510215A5 (enExample) | ||
| HRP20241153T1 (hr) | Postupci i sastavi za liječenje raka | |
| SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
| JP2012500001A5 (enExample) | ||
| PH12013500050A1 (en) | Anticancer fusion protein | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| CA2489227A1 (en) | Hla-a24-restricted cancer antigen peptides | |
| RU2011110504A (ru) | Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды | |
| JP2010506826A5 (enExample) | ||
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2025001402A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas | |
| JP2019533722A5 (enExample) | ||
| JP2015504052A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| JP2009533317A5 (enExample) | ||
| JP2012102105A5 (enExample) | ||
| JP2019537562A5 (enExample) | ||
| JP2018521977A5 (enExample) | ||
| JP2014533095A5 (enExample) | ||
| MX2017008994A (es) | Formulacion de peptidos inhibidores mk2. | |
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU |